BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)

Reports Q4 revenue $256,000, consensus $151,520. “2025 was a successful year for our Company, setting the stage for the potential label expansion of IGALMI in the at-home setting and continuing progress with commercial plans for the potential launch of IGALMI,” said Vimal Mehta, CEO of BioXcel Therapeutics (BTAI). “Our confidence in the substantial market opportunity in the at-home setting, where there are no FDA-approved options available, is reiterated by our recent market opportunity assessment. We also remain focused on advancing our Alzheimer’s dementia program, which is another large market opportunity.”